Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2020 in PKP2-ACM

Lexeo Therapeutics, Inc.

LX2020 generally well tolerated in 10 participants; no clinically significant complement activation observed
Mean PKP2 protein expression increased 93% in low-dose (n=2) and 162% in high-dose cohorts (n=5) by western blot
Non-sustained ventricular tachycardia reduced 22% (mean) in high-dose cohort (n=5); PVCs improved 14%
4 of 5 high-dose participants reported improvement on the PGIC patient-reported outcome scale
HEROIC-PKP2 enrollment completed Q4 2025; 12-month data for all high-dose participants expected Q4 2026

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.